ArticleBritish journal of clinical pharmacology2026
The persistence of chronic opioid use in patients with inflammatory bowel disease-A nationwide cohort study.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analgesic Use in Patients with Mild Inflammatory Bowel Disease-A Nationwide Cohort Study Based on Prescription Data.Journal of clinical medicine · 2026Article
- The persistence of chronic opioid use in patients with inflammatory bowel disease-A nationwide cohort study.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsPain is common in patients with Crohn's disease (CD) and ulcerative colitis (UC), and a substantial proportion develop chronic opioid use (COU). We examined the persistence of COU over time and identified factors predicting persistent use.
methodsThis nationwide Danish cohort study included patients with an initial period of COU (definition: ≥3 opioid prescriptions within 12 months with at least 30 days between prescriptions). We examined persistent COU for 2 years thereafter. Predictors for persistent COU were examined in multivariable logistic regression analyses.
resultsAmong 6208 patients with COU, 49.6% had persistent COU in the first follow-up year: 30.4% with only weak opioids, 11.7% with weak/strong opioids and 7.5% with only strong opioids. In the second follow-up year, two-thirds of those with persistent COU remained chronic users. Among 2553 patients with CD, key predictors of persistent COU in the first year of follow-up were age ≥70 years at disease onset (adjusted odds ratio [aOR] = 1.73, 95% CI: 1.22-2.45) and antidepressant use (aOR = 1.44, 95% CI: 1.18-1.75). Among the 3655 patients with UC, predictors included high comorbidity (aOR = 1.45, 95% CI: 1.05-2.00), age ≥70 years (aOR = 1.41, 95% CI: 1.09-1.82) and anxiolytic use (aOR = 1.38, 95% CI: 1.12-1.71).
conclusionsAfter an initial period of COU, half of all patients had persistent COU after 1 year, and among these two-thirds still had COU after an additional year. The main predictors of persistent COU were factors related to vulnerability (advanced age and mental health conditions).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.